Targeted Therapy for EGFR+ NSCLC: What Are the Current Options Upon Acquired Resistance to Osimertinib?

By GRACE FEATURING Zofia Piotrowska
By GRACE FEATURING Zofia Piotrowska
104 views
March 1, 2021
Comments 0
Login to view comments. Click here to Login